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The objective of this study was to compare the binding of cyclosporine to blood proteins 
between four healthy subjects and flYe liver and eight renal transplant patients. Fresh 
heparinized blood was obtained, to which suffIcient quantities of tritium-labelled cyclo-
sporine and unlabelled cyc1osporine were added to blood samples or red blood cell (RBC) 
suspensions. Concentrations of cyc1osporine in whole blood, plasma, RBC suspension, and 
phosphate buffer were estimated by liquid scintigraphy. The blood:plasma ratio of 
CYc1osporine in transplant patients was significantly lower (P < .05) than that in healthy 
volunteers. The RBC:buffer ratio, a measure of affinity of RBCs for cyc1osporine, was 
highest in those with liver transplants and lowest in those with kidney transplants. The 
unbound fraction of cyclosporine in plasma was less in transplant patients than in healthy 
volunteers. The results of this study indicate that there are differences in blood protein 
binding of cyc1osporine between transplant patients that may contribute to the differ-
ences in the pharmacokinetics and pharmacodynamics of this drug. 
P lasma protein binding is an important determinant of drug disposition. The binding of drugs to plasma pro-
teins is influenced by a variety of factors. 1 The effect of 
changes in protein binding on drug kinetics and drug 
activity depends on the kinetic property and the therapeutic 
index of the drug. Cyclosporine exhibits marked variability 
in its kinetics between patients.2 It is known to be highly 
bound to plasma proteins in healthy subjects.3•4 The objec-
tive of our study was to compare the binding of cyclosporine 
to blood proteins between healthy subjects and liver and 
renal transplant patients. 
PATIENTS AND METHODS 
Fresh heparinized blood was obtained from eight kidney 
transplant patients, fIve liver transplant patients, and four 
healthy volunteers. All the patients were clinically stable. 
The plasma unbound fraction of cyclosporine was estimat-
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ed using a modincation of the partitioning method of 
Garrett and colleagues.5 
Sufficient quantities of tritium-labelled cyclosporine and 
unlabelled cyclosporine were added to blood samples or 
red blood cell suspensions in order to achieve a tinal 
concentration of about 300 ng/mL. The red blood cell: 
plasma distribution ratio was estimated following incuba-
tion of blood samples for one hour at 37°C. Distribution 
equilibrium between blood cells and plasma is observed 
within 60 minutes.6 The whole blood was centrifuged at 
37°C in order to obtain plasma. Red blood cell to buffer 
partitioning of cyclosporine was estimated in blood cells. 
isolated from whole blood. washed three times with isotonic 
phosphate buffer. and resuspended in phosphate buffer to 
the initial hematocrit values. Red blood cell suspensions 
were incubated for 15 minutes at 37°C. Preliminary studies 
indicated that equilibrium between red blood cells and 
buffer is rapid and complete within ten minutes.6 The con-
centrations of cyclosporine in whole blood. plasma. red 
blood cell suspension. and buffer were estimated by a liq-
uid scintillation spectrometer using the channels ratio meth-
od for quench correction. Whole blood and red blood cell 
suspensions were counted after bleaching. according to 
standard techniques.7 The unbound fraction of cyclosporine 
in plasma was calculated with the following equation 
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BLOOD PROTEIN BINDING OF CYCLOSPORINE 
in which WB is the concentration of cycJosporine in whole 
blood. P is the concentration in plasma. RBC is the concen-
tration of drug in red blood cells. B is the concentration of 
cyc1osporine in buffer. H is the hematocrit. and B/P is the 
unbound fraction of cyc1osporine in plasma. A t test for 
independent samples was used to compare different param-
eters obtained in transplant patients with that of healthy 
volunteers. A P value of less than or equal to .05 was 
considered to indicate signifIcant differences in the param-
eters estimated between different groups studied. 
RESULTS 
The blood:plasma ratio of cycJosporine in kidney and liver 
transplant patients was significantly [P < .05] lower than that 
in healthy volunteers (Table]. Liver and kidney transplant 
patients also had a lower hematocrit level as compared with 
healthy subjects IP < .05]. The RBC:buffer ratio. which is a 
measure of the affinity of red blood cells for cycJosporine. 
was very high in all of the subjects studied. The RBC:buffer 
ratio was highest for the liver transplant group and lowest for 
the renal transplant group. The mean ± standard deviation 
RBC:buffer ratio was 13.5 ± 3.5. 26.0 ± 3.0. and 19.0 ± 0.7 in 
kidney and liver transplant patients and healthy volunteers. 
respectively. This ratio was fairly constant in liver transplant 
patients and in healthy subjects but varied more than twofold 
in renal transplant patients. The unbound fraction of cycJo-
sporine in plasma was significantly smaller (P < .01) in liver 
[0.08) and kidney [0.09) transplant patients as compared with 
healthy volunteers (0.17). The unbound fraction in plasma 
ranged from 0.05 to 0.20 in our study population. with 
considerable variability being observed in the renal trans-
plant patients. The mean unbound fraction in blood was 
similar to the mean un bound fraction in plasma of renal and 
liver transplant patients. but smaller in healthy subjects. The 
unbound fraction in blood varied threefold in renal trans-
plant patients but was less variable among liver transplant 
patients and healthy subjects. 
DISCUSSION 
Traditional methods of determining the protein binding of 
drugs could not be used in the present study. SignifIcant 
losses of cycJosporine were observed in the equilibrium 
TABLE 
Blood Protein Binding of Cyclosporine 
Subjects WB/P RBe/B B/P H B/WB 
Kidney Transplant 
1 1.35 18.94 0.11 0.35 0.081 
2 1.02 13.42 0.08 0.36 0.078 
3 0.85 10.44 0.06 0.43 0.071 
4 1.15 8.84 0.16 0.39 0.139 
5 0.94 17.25 0.05 0.28 0.053 
6 0.93 12.90 0.06 0.37 0.065 
7 0.91 15.02 0.04 0.23 0.044 
8 1.21 10.95 0.17 0.25 0.140 
Mean ± SO 1.05 ± 0.17* 13.47 ± 3.46* 0.09 ± 0.05* 0.33 ± 0.07* 0.084 ± 0.036 
Liver Transplant 
1 1.59 29.15 0.10 0.31 0.063 
2 1.36 29.60 0.08 0.24 0.059 
3 1.27 24.04 0.08 0.31 0.063 
4 1.29 24.04 0.08 0.31 0.062 
5 1.12 23.55 0.06 0.28 0.054 
Mean ± SO 1.33 ± 0.17* 26.08 ± 3.02* 0.08 ± 0.01" 0.29 ± 0.03* 0.060 ± 0.004* 
Healthy Subjects 
1 1.69 19.19 0.14 0.43 0.083 
2 2.06 19.15 0.20 0.39 0.097 
3 2.05 19.60 0.17 0.45 0.083 
4 1.93 17.97 0.19 0.39 0.098 
Mean ± SO 1.93 ± 0.17 18.98 ± 0.70 0.17 ± 0.03 0.41 ± 0.03 0.090 ± 0.01 
'Slgnificantly different from healthy subjects (P < .05). 
WB = cyclosporine concentration in whole blood; P = in plasma; RBe = in red blood cells; B = in buffer; H = In hematocnt. 
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dialysis and ultrafiltration methods. presumably because of 
binding of cyclosporine to membranes and filters used with 
these techniques. Ultracentrifugation requires special 
instrumentation and severe experimental conditions such as 
high temperature (37°q and prolonged centrifugation (16 
huursl al high speeds (15.000 g).3 Preliminary ultracentrifuge 
sludies indicaled incomplele separation of proteins from 
plasma waler even under such rigorous conditions. We 
therefore used a partitioning method 10 sludy the binding of 
cyclosporine 10 plnsma proteins. This method yields results 
Ihat are comparable to that obtained by equilibrium dialysis 
and ultraflliralion for amitriptyline. imipramine. quinidine. 
lidocaine. and proprnnolol.8 This method also provides 
informalion on the erythrocyte uptake of cyclosporine. This 
method requires that the uptake of drugs into blood cells 
and the binding of drugs to plnsma protein be linear at the 
cnncentrntions used. Preliminary studies in our laboratory 
established that the red blood celluJltake of cyclosporine is 
Iinenr or concentration-independent lip to 800 ng/mL. In 
the present study. we used u concentration of only 300 
ng/mL of cyclosporine. FlIJ'ther evidence in the Iilerature 
indicates Ihat the plasma protein binding of cyclospurine is 
also lineal' up to 5.000 ng/mL.4 Estimations of RBC:lmffer 
and blood:plasma ratios and unbound fraclions by this 
method were very reproducible with a coefficient of varia-
tion of 5.3';;,·. 6.8%. and 7.8'/'" respectively (n = 3). 
As shown in the equation. the whole bloud:plasma ratio 
of a drug depends on the hematocrit level. RBC:buffer ratio 
(RUC uptake]. and B/P (unbound frnclion in plasma). The 
wide variation in the whule hlood:plasma ralio ohserved in 
our study is nllributable to the combined effects of differ-
ences in hematocrit levels, RBC uptake. and the unbound 
fractiun of cyclosporine in plasma between the different 
groups. Liver nnd renal transplant paticnts often have a low 
hematocrit concentrntion as compared with hea IIhy suo-
jects. The fraction of the drug in hlood that resides in 
plasma is inversely corrclnteo with the hematocrit valueY 
Therefore. for a given whole blood concentration. more 
drug will be distributed in the plasma in these patients. 
Although cyclosporine was highly sequestered by RBC in 
all individuals. the uptake was lower in renal transplant 
patients. The rensons for the poor uptake of cyclosporine by 
RAC oblained from renaltransplanl patients is not c1eur at 
present. but may be relaled to qualitative und quantitutive 
differences in Ihe componenl responsible fur drug binding 
to erythrocytes. 
Cyclosporine is primarily bound to lipoproteins in plas-
ma. The large variation in the unbound fraction of cyclo-
sporine in different patients may be u reflection of possible 
differences in Iho concentration of lipoproteins in the 
plasma of liwse suhjects. A high incidence of nn abnormnl 
plasma lipid profile hilS been reporled in renal transplant 
patients.1fI·11 Presently. there is no information available on 
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the lipoprotein profIles in liver transplant patients. lipopro-
tein pronles were not estimated in our study participants. 
The contribution of altered lipoprotein concentmtions to the 
variability observed in the unbound fraction of cyclosporine 
could not be evaluated in the present study. 
A combination of altered lipoprotein pron Ie and variable 
hematocrit will result in marked differences in the unbound 
fraction of cyclosporine in the blood of transplant patients. 
Since cyclosporine is a low- to intermediate-clearance drug. 
its clearance is dependent on its unbound fmction in blood. 
Wide variations in the unbound fraction will therefore 
contribute to the wide variability in the clearance of 
cyclosporine observed in transplant patients. In addition. 
since hematocrit and lipoprotein concentrulions change 
with time after transplant. time-dependent changes in blood 
protein binding and clearance of cyclosporine would also 
be expected. 
The results of our study indicate that there arc differences 
in blood protein binding of cyclosporine between transplant 
patients. This may contribute to the differences in the 
pharmacokinetics and pharmacodynamics of this immuno-
suppressant. Future studies should characterize the phar-
macokinetics of unbound cyclosporine in bluod. 
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